Abstract Library

#4336 Life-threatening hypoglycaemia due to insulinoma successfully treated with PRRT

Introduction: Malignant insulinoma is an uncommon tumour that is usually accompanied by severe hypoglycaemia.

Conference:

Presenting Author:

Authors: Ledwon A, Michalik B, Kropinska A, Paliczka-Cieslik E, Blewaska A,

Keywords: insulinoma, sever hypoglycaemia, PRRT,

#3842 Long response to 177-Lu DOTATATE of a long malignant metastatic pheochromocytoma survivor

Introduction: A 64-year-old man was admitted on November 2010 with a CT-scan showing a 9cm right adrenal mass and high 24-hour urine metanephrins and cathecolamins. The mass was resected in December 2010 confirming a pT3N1 pheochromocytoma (PHEO). In May 2013 he presented a local recurrence that was resected proving metastatic lymphatic tissue. On May 2014 biochemical progression preceded a CT scan showing retroperitoneal lymphadenophaties with MIBG uptake. He was then treated with 131I-MIBG (two cycles) until May 2015, having biochemical and radiological response. After lymphatic tumor progression in January 2018, he received two more cycles of 131I-MIBG therapy (cumulative dose 800mCi) with proven refractory disease. He continued follow-up until two new abdominal masses appeared in October 2020. A high uptake in the 99Tc octreotide scintigraphy showed somatostatin receptors expression. The patient refused to participate in a clinical trial, so he was treated off-label with 177Lu-DOTATATE (800mCi) four doses from February to July 2021 achieving a near-complete response.

Conference:

Presenting Author: Martin Fernandez de Soignie A

Authors: Martin Fernandez de Soignie A, Martinez Moreno E, Antón-Pascual B, Pantin Gonzalez C, Sanchez Baños N,

Keywords: pheochromocytoma, 177-Lutetium,

#3491 Renal uptake monitoring during different cycles of 90Y-DOTATOC therapy based on 111In and 90Y SPECT imaging

Introduction: Unresectable or borderline resectable WHO G1/G2 P-NETs patients with limited liver disease are treated with 6 90Y-DOTATOC therapy cycles within a clinical protocol. Kidney dosimetry is performed at first cycle. Assuming equal absorbed dose for all cycles, cycles are reduced if cumulative dose exceeds kidney toxicity limits.

Conference:

Presenting Author: d'Arcangelo M

Authors: d'Arcangelo M, Botta F, Ferrari M, Ghisini R, Fodor C,

Keywords: dosimetry, PRRT, 90Y,

#3213 Hyponatremia and hypernatremia have an opposing effect on overall survival in neuroendocrine tumor patients treated with peptide receptor radionuclide therapy

Introduction: Hypo- and hypernatremia are common electrolyte abnormalities in patients with malignancy and have been independently associated with worse survival outcomes. To date, there is no data on the influence of dysnatremia on patients with neuroendocrine tumors (NET).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Refardt J, Brabander T, Minczeles N, Feelders R, de Herder W,

Keywords: hyponatremia, hypernatremia, survival, PRRT,

#2292 PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Brabander T, Kam B, Teunissen J, Krenning E,

Keywords: Salvage, PRRT, Re-treatment, GEP-NET, Safety, Efficacy, 177Lu-DOTATATE,